NovoCure (NVCR) has experienced significant price fluctuations driven by a combination of a strong second-quarter earnings report that exceeded expectations, positive operational growth, and an improved profitability outlook, which has helped to offset lingering concerns from a prior clinical trial setback.

Key Factors Contributing to Volatility:

Strong Q2 2026 Earnings Beat: NovoCure reported a Q2 2026 loss of -$15.7 million, or $0.13 per share, significantly outperforming analysts' consensus estimates of a $0.33 loss per share. Revenue also surpassed expectations, reaching $183.6 million against an anticipated $172.4 million. This strong beat led to the stock surging 28% following the announcement.
Record Revenue and Patient Growth: Net revenues increased by 16% year-over-year to $183.6 million, propelled by an 18% growth in global active patients, reaching a record 5,128. The company's main product, Optune Gio, continued to drive growth, with newer therapies Optune Lua and Optune Pax also showing early promise.
Improved Profitability and Outlook: Although the company still posted a net loss, the -$15.7 million loss was a substantial improvement from the prior year's $0.36 loss per share. Adjusted EBITDA turned positive at $11 million, a significant turnaround from a $10 million loss in the same period last year. NovoCure also raised its full-year revenue guidance and anticipates achieving adjusted EBITDA breakeven for the full year 2026.
Gross Margin Expansion: The company's gross profit margin expanded to 78%, partly due to a one-time tariff refund and lower array costs, reflecting improved operational efficiencies.
Impact of Previous Clinical Trial Results and Future Catalysts: The positive earnings news follows a late-stage trial failure for Optune Gio, which did not show statistically significant overall survival benefit for earlier use in glioblastoma, a factor that likely contributed to prior volatility. However, upcoming catalysts, such as an anticipated FDA decision in Q4 2026 for TTFields therapy in brain metastases, are contributing to renewed investor interest.

Income Overview

Time Plot

Income Statement

Income Overview

Time Plot

Income Statement